Clinical trial
Rituximab and Oblimersen in Treating Patients With Stage II, Stage III, or Stage…
NCT00301795 · National Cancer Institute (NCI), NIH · Terminated
Key facts
| NCT number | NCT00301795 |
|---|---|
| Title | Rituximab and Oblimersen in Treating Patients With Stage II, Stage III, or Stage IV Follicular Non-Hodgkin's Lymphoma |
| Official title | A Phase II Trial of Rituximab + Oblimersen Sodium (GenasenseTM, G3139, NSC #683428, IND #58842) in Patients With Previously Untreated Follicular Non-Hodgkin Lymphoma (NHL) |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Stage III Grade 1 Follicular Lymphoma, Stage III Grade 2 Follicular Lymphoma, Stage III Grade 3 Follicular Lymphoma, Stage IV Grade 1 Follicular Lymphoma, Stage IV Grade 2 Follicular Lymphoma, Stage IV Grade 3 Follicular Lymphoma |
| Intervention type | Biological, Other |
| Interventions | oblimersen sodium, rituximab, laboratory biomarker analysis |
| Enrollment | 52 |
| Start date | Mar 1, 2006 |
| Primary completion | Nov 1, 2007 |
| First posted | Mar 13, 2006 |
| Last update posted | Jan 7, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: